-
1
-
-
84901193103
-
Oncolytic viruses for cancer treatment
-
Goldufsky, J., Sivendran, S., Harcharik, S., et al. (2013). Oncolytic viruses for cancer treatment. Oncolytic Virother. 2, 31-46.
-
(2013)
Oncolytic Virother.
, vol.2
, pp. 31-46
-
-
Goldufsky, J.1
Sivendran, S.2
Harcharik, S.3
-
2
-
-
84884902793
-
SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence
-
Grupp, K., Diebel, F., Sirma, H., et al. (2013a). SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate 73, 1690-1698.
-
(2013)
Prostate
, vol.73
, pp. 1690-1698
-
-
Grupp, K.1
Diebel, F.2
Sirma, H.3
-
3
-
-
84884344385
-
Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy
-
Grupp, K., Hohne, T.S., Prien, K., et al. (2013b). Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Exp. Mol. Pathol 95, 227-234.
-
(2013)
Exp. Mol. Pathol
, vol.95
, pp. 227-234
-
-
Grupp, K.1
Hohne, T.S.2
Prien, K.3
-
4
-
-
49649090374
-
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
-
Gulley, J.L., Arlen, P.M., Tsang, K.Y., et al. (2008). Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14, 3060-3069.
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 3060-3069
-
-
Gulley, J.L.1
Arlen, P.M.2
Tsang, K.Y.3
-
5
-
-
84883458734
-
Phase i study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer
-
Gulley, J.L., Heery, C.R., Madan, R.A., et al. (2013). Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol. Immunother. 62, 1521-1531.
-
(2013)
Cancer Immunol. Immunother.
, vol.62
, pp. 1521-1531
-
-
Gulley, J.L.1
Heery, C.R.2
Madan, R.A.3
-
6
-
-
0344412934
-
Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses
-
Hodge, J.W., Poole, D.J., Aarts, W.M., et al. (2003). Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63, 7942-7949. (Pubitemid 37466731)
-
(2003)
Cancer Research
, vol.63
, Issue.22
, pp. 7942-7949
-
-
Hodge, J.W.1
Poole, D.J.2
Aarts, W.M.3
Yafal, A.G.4
Gritz, L.5
Schlom, J.6
-
7
-
-
77957253429
-
OPTIM trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
-
Kaufman, H.L., and Bines, S.D. (2010). OPTIM trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 6, 941-949.
-
(2010)
Future Oncol.
, vol.6
, pp. 941-949
-
-
Kaufman, H.L.1
Bines, S.D.2
-
8
-
-
0038359163
-
Clinical protocol: Intra-lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer
-
Kaufman, H.L., Cheung, K., Haskall, Z., et al. (2003). Clinical protocol: Intra-lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer. Hum. Gene Ther. 14, 803-827.
-
(2003)
Hum. Gene Ther.
, vol.14
, pp. 803-827
-
-
Kaufman, H.L.1
Cheung, K.2
Haskall, Z.3
-
9
-
-
2942644684
-
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the eastern cooperative oncology group
-
Kaufman, H.L., Wang, W., Manola, J., et al. (2004). Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22, 2122-32.
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 2122-2132
-
-
Kaufman, H.L.1
Wang, W.2
Manola, J.3
-
10
-
-
22144457398
-
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma
-
Kaufman, H.L., Deraffele, G., Mitcham, J., et al. (2005). Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J. Clin. Invest. 115, 1903-1912.
-
(2005)
J. Clin. Invest.
, vol.115
, pp. 1903-1912
-
-
Kaufman, H.L.1
Deraffele, G.2
Mitcham, J.3
-
11
-
-
33144480152
-
Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors
-
Kaufman, H.L., Cohen, S., Cheung, K., et al. (2006). Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum. Gene Ther. 17, 239-244.
-
(2006)
Hum. Gene Ther.
, vol.17
, pp. 239-244
-
-
Kaufman, H.L.1
Cohen, S.2
Cheung, K.3
-
12
-
-
77149141965
-
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
-
Kaufman, H.L., Kim, D.W., Deraffele, G., et al. (2010). Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718- 730.
-
(2010)
Ann. Surg. Oncol.
, Issue.17
, pp. 718-730
-
-
Kaufman, H.L.1
Kim, D.W.2
Deraffele, G.3
-
13
-
-
67650309082
-
Gene therapy for antitumor vaccination
-
Kim-Schulze, S., and Kaufman, H.L. (2009). Gene therapy for antitumor vaccination. Methods Mol. Biol. 542, 515-527.
-
(2009)
Methods Mol. Biol.
, vol.542
, pp. 515-527
-
-
Kim-Schulze, S.1
Kaufman, H.L.2
-
14
-
-
84879947917
-
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions
-
Kluth, M., Hesse, J., Heinl, A., et al. (2013). Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod. Pathol. 26, 975-983.
-
(2013)
Mod. Pathol.
, vol.26
, pp. 975-983
-
-
Kluth, M.1
Hesse, J.2
Heinl, A.3
-
15
-
-
15444372996
-
Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection [5]
-
DOI 10.1111/j.1075-122X.2005.21627.x
-
Komenaka, I.K., Deraffele, G., Hurst-Wicker, K.S., and Kaufman H.L. (2005). Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection. Breast J. 11, 158-159. (Pubitemid 40396795)
-
(2005)
Breast Journal
, vol.11
, Issue.2
, pp. 158-159
-
-
Komenaka, I.K.1
Deraffele, G.2
Hurst-Wicker, K.S.3
Kaufman, H.L.4
-
16
-
-
0034551730
-
Phase i study in advanced cancer patients of a diversified primeand- boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
-
Marshall, J.L., Hoyer, R.J., Toomey, M.A., et al. (2000). Phase I study in advanced cancer patients of a diversified primeand- boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964-73.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 3964-3973
-
-
Marshall, J.L.1
Hoyer, R.J.2
Toomey, M.A.3
-
17
-
-
84891428389
-
DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer
-
Moritz, R., Ellinger, J., Nuhn, P., et al. (2013). DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer. Anticancer Res. 33, 5249-5254.
-
(2013)
Anticancer Res.
, vol.33
, pp. 5249-5254
-
-
Moritz, R.1
Ellinger, J.2
Nuhn, P.3
-
18
-
-
28844444483
-
Recent progress in the battle between oncolytic viruses and tumours
-
DOI 10.1038/nrc1750
-
Parato, K.A., Senger, D., Forsyth, P.A., and Bell, J.C. (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5, 965-76. (Pubitemid 41766784)
-
(2005)
Nature Reviews Cancer
, vol.5
, Issue.12
, pp. 965-976
-
-
Parato, K.A.1
Senger, D.2
Forsyth, P.A.J.3
Bell, J.C.4
-
19
-
-
0028052724
-
Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide sidechains
-
Parker, K.C., Bednarek, M.A., and Coligan, J.E. (1994). Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide sidechains. J. Immunol. 152, 163-175.
-
(1994)
J. Immunol.
, vol.152
, pp. 163-175
-
-
Parker, K.C.1
Bednarek, M.A.2
Coligan, J.E.3
-
20
-
-
33846894323
-
SHIV elicit both neutralizing antibodies and IFNγ-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells
-
DOI 10.1016/j.vaccine.2006.11.009, PII S0264410X06011984
-
Radaelli, A., Bonduelle, O., Beggio, P., et al. (2007). Prime- boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNγ-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine 25, 2128-2138. (Pubitemid 46227664)
-
(2007)
Vaccine
, vol.25
, Issue.11
, pp. 2128-2138
-
-
Radaelli, A.1
Bonduelle, O.2
Beggio, P.3
Mahe, B.4
Pozzi, E.5
Elli, V.6
Paganini, M.7
Zanotto, C.8
Morghen, C.D.G.9
Combadiere, B.10
-
21
-
-
0032866605
-
The diversity of T-cell co-stimulation in the induction of antitumor immunity
-
DOI 10.1111/j.1600-065X.1999.tb01330.x
-
Schlom, J., and Hodge, J.W. (1999). The diversity of T-cell costimulation in the induction of antitumor immunity. Immunol. Rev 170, 73-84. (Pubitemid 29490746)
-
(1999)
Immunological Reviews
, vol.170
, pp. 73-84
-
-
Schlom, J.1
Hodge, J.W.2
-
22
-
-
73349133717
-
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma
-
Senzer, N.N., Kaufman, H.L., Amatruda, T., et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763-5771.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 5763-5771
-
-
Senzer, N.N.1
Kaufman, H.L.2
Amatruda, T.3
-
23
-
-
77953348107
-
Herpes simplex virus oncolytic vaccine therapy in melanoma
-
Sivendran, S., Pan, M., Kaufman, H.L., and Saenger, Y. (2010). Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin. Biol. Ther. 10, 1145-1153.
-
(2010)
Expert Opin. Biol. Ther.
, vol.10
, pp. 1145-1153
-
-
Sivendran, S.1
Pan, M.2
Kaufman, H.L.3
Saenger, Y.4
-
24
-
-
84879421374
-
Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers
-
Stumm, L., Burkhardt, L., Steurer, S., et al. (2013). Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. J. Clin. Pathol. 66, 563-568.
-
(2013)
J. Clin. Pathol.
, vol.66
, pp. 563-568
-
-
Stumm, L.1
Burkhardt, L.2
Steurer, S.3
-
25
-
-
0025178584
-
Poxvirusbased vectors as vaccine candidates
-
Tartaglia, J., Pincus, S., and Paoletti, E. (1990). Poxvirusbased vectors as vaccine candidates. Crit Rev Immunol. 10, 13-30.
-
(1990)
Crit Rev Immunol.
, vol.10
, pp. 13-30
-
-
Tartaglia, J.1
Pincus, S.2
Paoletti, E.3
-
26
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
european Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. (2000). New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205-216.
-
(2000)
J. Natl. Cancer Inst.
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
27
-
-
84882450205
-
High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy
-
Tsourlakis, M.C., Walter, E., Quaas, A., et al. (2013). High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy. Prostate Cancer Prostatic Dis. 16, 159- 164.
-
(2013)
Prostate Cancer Prostatic Dis.
, vol.16
, pp. 159-164
-
-
Tsourlakis, M.C.1
Walter, E.2
Quaas, A.3
|